Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial - PubMed (original) (raw)
Clinical Trial
. 2011 Jun;10(6):1102-12.
doi: 10.1158/1535-7163.MCT-11-0048. Epub 2011 Apr 6.
Annie-Claire Diserens, Pierre Bady, Yuta Kamoshima, Mathilde C M Kouwenhoven, Mauro Delorenzi, Wanyu L Lambiv, Marie-France Hamou, Matthias S Matter, Arend Koch, Frank L Heppner, Yasuhiro Yonekawa, Adrian Merlo, Karl Frei, Luigi Mariani, Silvia Hofer
Affiliations
- PMID: 21471286
- DOI: 10.1158/1535-7163.MCT-11-0048
Free article
Clinical Trial
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial
Monika E Hegi et al. Mol Cancer Ther. 2011 Jun.
Free article
Abstract
Amplification of the epidermal growth factor receptor (EGFR) gene is one of the most common oncogenic alterations in glioblastoma (45%) making it a prime target for therapy. However, small molecule inhibitors of the EGFR tyrosine kinase showed disappointing efficacy in clinical trials for glioblastoma. Here we aimed at investigating the molecular effects of the tyrosine kinase inhibitor gefitinib on the EGFR signaling pathway in human glioblastoma. Twenty-two patients selected for reoperation of recurrent glioblastoma were treated within a phase II trial for 5 days with 500 mg gefitinib before surgery followed by postoperative gefitinib until recurrence. Resected glioblastoma tissues exhibited high concentrations of gefitinib (median, 4.1 μg/g), 20 times higher than respective plasma. EGFR-pathway activity was evaluated with phosphorylation-specific assays. The EGFR was efficiently dephosphorylated in treated patients as compared to a control cohort of 12 patients. However, no significant effect on 12 pathway constituents was detected. In contrast, in vitro treatment of a glioblastoma cell line, BS-153, with endogenous EGFRwt amplification and EGFRvIII expression resulted not only in dephosphorylation of the EGFR, but also of key regulators in the pathway such as AKT. Treating established xenografts of the same cell line as an in vivo model showed dephosphorylation of the EGFR without affecting downstream signal transductors, similar to the human glioblastoma. Taken together, gefitinib reaches high concentrations in the tumor tissue and efficiently dephosphorylates its target. However, regulation of downstream signal transducers in the EGFR pathway seems to be dominated by regulatory circuits independent of EGFR phosphorylation.
Trial registration: ClinicalTrials.gov NCT00250887.
Similar articles
- Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Learn CA, et al. Clin Cancer Res. 2004 May 1;10(9):3216-24. doi: 10.1158/1078-0432.ccr-03-0521. Clin Cancer Res. 2004. PMID: 15131063 - InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J. Ma Y, et al. Clin Cancer Res. 2016 Apr 1;22(7):1767-76. doi: 10.1158/1078-0432.CCR-15-1677. Epub 2015 Nov 11. Clin Cancer Res. 2016. PMID: 26561558 Free PMC article. - A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Haura EB, Sommers E, Song L, Chiappori A, Becker A. Haura EB, et al. J Thorac Oncol. 2010 Nov;5(11):1806-14. doi: 10.1097/JTO.0b013e3181f38f70. J Thorac Oncol. 2010. PMID: 20881637 Free PMC article. - Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
Penne K, Bohlin C, Schneider S, Allen D. Penne K, et al. Cancer Nurs. 2005 Nov-Dec;28(6):481-6. doi: 10.1097/00002820-200511000-00012. Cancer Nurs. 2005. PMID: 16330971 Review. - Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B, Szep E, Garzuly F, Post DE. Kalman B, et al. Neuromolecular Med. 2013 Jun;15(2):420-34. doi: 10.1007/s12017-013-8229-y. Epub 2013 Apr 11. Neuromolecular Med. 2013. PMID: 23575987 Review.
Cited by
- Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials.
Hoosemans L, Vooijs M, Hoeben A. Hoosemans L, et al. Cancers (Basel). 2024 Aug 29;16(17):3021. doi: 10.3390/cancers16173021. Cancers (Basel). 2024. PMID: 39272879 Free PMC article. Review. - vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.
Manzanares-Guzmán A, Lugo-Fabres PH, Camacho-Villegas TA. Manzanares-Guzmán A, et al. Antibodies (Basel). 2024 Mar 18;13(1):25. doi: 10.3390/antib13010025. Antibodies (Basel). 2024. PMID: 38534215 Free PMC article. Review. - Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM, Marqués-Torrejón MÁ. Obrador E, et al. Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review. - Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).
Yashin KS, Yuzhakova DV, Sachkova DA, Kukhnina LS, Kharitonova TM, Zolotova AS, Medyanik IA, Shirmanova MV. Yashin KS, et al. Sovrem Tekhnologii Med. 2023;15(3):61-71. doi: 10.17691/stm2023.15.3.07. Epub 2023 May 28. Sovrem Tekhnologii Med. 2023. PMID: 38435477 Free PMC article. Review. - Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S, Salib S, Balasubramaniam M, Aboud O. Ezzati S, et al. Int J Mol Sci. 2024 Feb 15;25(4):2316. doi: 10.3390/ijms25042316. Int J Mol Sci. 2024. PMID: 38396993 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous